A Study on the Safety and Efficacy of Adenosylcobalamin in Patients With Declining Ovarian Function
The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:
Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?
Participants will:
Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 4
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Liru Xue
- Telefoonnummer: CN 18727297670
- E-mail: 751400767@qq.com
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Premature Ovarian Insufficiency (POI): Age < 40 years old, with two consecutive basal FSH levels ≥ 25 U/L spaced 4 weeks apart, decreased anti-müllerian hormone (AMH), and clinical manifestations of oligomenorrhea or amenorrhea.
(2) Diminished ovarian reserve (DOR): Age < 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (< 6) and/or an elevated basal FSH level (> 10 U/L).
Exclusion Criteria:
- Abnormal uterine bleeding of unknown cause;
- Presence of ovarian/appendage masses ≥ 4 cm, uterine adenomyosis, uterine adenomyoma/uterine fibroids ≥ 4 cm;
- BI-RADS rating of breast ultrasound ≥ 4;
- Presence of precancerous lesions or having malignant tumors;
- Liver and kidney function indicators (ALT, AST, Urea, Cr) exceed the upper limit of normal reference values and have not returned to normal after re-examination;
- Complicated with severe primary diseases in the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems, or patients with mental disorders;
- Have received systemic hormone replacement therapy within the last 2 months;
- Are participating in other clinical trials or have participated in other clinical trials within the last 1 month;
- Have a recent fertility requirement;
- Other patients deemed unsuitable for participation in this study by the researchers.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: POI and DOR
|
Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
anti-müllerianhormone
Tijdsspanne: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
sex hormones
Tijdsspanne: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
antral follicles
Tijdsspanne: Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- TJ-IRB202611089
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .